Tumours historically are divided into phenotypes according to CD8+ T cell distribution, while CD8+ T cells are known to be the most powerful effectors in the anticancer immune response or according to total lymphocyte distribution in tumour tissue [35]. This evidence concerns the gene CD8A and neoplasm.